These results were not consistent with other studies that showed that MTHFR rs1801133 polymorphism modifies the toxicity of MTX and indicates that patients with the TT genotype are at increased risk of developing hyperhomocysteinemia after MTX treatment in patients with ovarian cancer [18]. This evidence concerns the gene MTHFR and hyperhomocysteinemia.